🔴 BreakingNewsFDAThursday, April 23, 2026 · April 23, 2026
FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program
WHY IT MATTERS
FDA announcement relevant to rare disease patients and caregivers.
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy.
Related news
FDA
FDA Approves XTORO
XTORO (FINAFLOXACIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…
FDA
FDA Approves SABRIL
SABRIL (VIGABATRIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…